TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01715675

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant stanol enriched soy-based yoghurt
Description: Plant stanol enriched soy-based yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy-based yoghurt without added plant stanols
Description: Soy-based yoghurt without added plant stanols
Study: NCT02658110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Macronutrient Lunch Meal
Description: A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Macronutrient Lunch Meal
Description: A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
Study: NCT03032003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cysticlean
Description: 2 BID for 15 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 BID for 15 days
Study: NCT04251533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpelisib
Description: 300 mg orally, once per day (QD), tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpelisib
Description: 300 mg orally, once per day (QD), tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 300 mg orally, once per day (QD), tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/m\^2 IV infusion, once per day (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nab-paclitaxel
Description: 100 mg/m\^2 IV infusion, once per day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 100 mg/m\^2 IV infusion, once per day (QD)
Study: NCT00858390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral feeding with Oxepa® and Glutasolve®
Description: enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
Study: NCT01502319

Intervention type: BEHAVIORAL
Intervention: Cognitive therapy
Description: Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
Study: NCT02544438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astarabine (BST-236)
Description: Cohort # Astarabine Dose Number of Patients~1. 0.5 gr/m2 (0.3 age\>50) 3~2. 1.5 gr/m2(0.8age\>50) 3~3. 3.0 gr/m2(1.5 age\>50) 3~4. 4.5 gr/m2(2.3 age\>50) 6~5. 4.5 gr/m2 (no age limit) 3 up to 6~6. 6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24
Study: NCT01299103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelleve Wrinkle Treatment System
Description: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
Study: NCT03669965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth
Study: NCT01299103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelleve Wrinkle Treatment System
Description: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pelleve Wrinkle Treatment System
Description: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
Study: NCT03093142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS & neurofeedback
Description: tDCs and neurofeedback

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neurofeedback
Description: Neurofeedback
Study: NCT03653754

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of growth and body composition
Description: Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of growth and body composition
Description: Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
Study: NCT01482104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAL-PDT re-treatment
Description: a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual MAL-PDT
Description: schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
Study: NCT02961426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir + ravidasvir
Description: combination of sofosbuvir + ravidasvir
Study: NCT01441427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human G-CSF, and rhEPO
Description: G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
Study: NCT03669965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib per approved prescribing label
Study: NCT04279054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate 150 mcg
Description: Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
Study: NCT01441427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh G-CSF
Description: Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh EPO
Description: Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rh G-GSF and rh EPO together
Description: EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
Study: NCT04279054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate 50mcg
Description: Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
Study: NCT03670277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Test Soft Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual Orthokeratology Lenses
Description: CONTROL
Study: NCT02425358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMC therapy within 24 hours
Description: The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMC therapy within 3-7 days
Description: Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
Study: NCT01441427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
Study: NCT03490084

Intervention type: OTHER
Intervention: Association of day hospitalization with hospital-at-home
Description: Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.

Intervention type: OTHER
Intervention: Day hospitalization exclusively
Description: Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
Study: NCT02425358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMC therapy within 7-30 days
Description: Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCI only
Description: The saline was intracoronary infusion with the use of microtubular.
Study: NCT03609970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily 4X 1000IU cholecalciferol
Study: NCT02999958

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants
Description: In the Treatment Arm, the G-Series culture media system will be used with antioxidants
Study: NCT03726112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpotOn Specs
Description: SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Specs
Description: Sham device
Study: NCT04514991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foundation
Description: Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
Study: NCT03417141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechlorethamine 0.016% Top Gel
Description: Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
Study: NCT00095784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00464724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3T Magnetic Resonance Spectroscopic Imaging
Description: Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
Study: NCT04053374

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling +/- CSF sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling +/- CSF sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling +/- CSF sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling +/- CSF sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling +/- CSF sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling +/- CSF sampling
Study: NCT00433693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week
Study: NCT01512719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: Per Oral Endoscopic Myotomy for achalasia
Study: NCT03565185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted gait training
Description: Investigators will use robot-assisted gait training for rehabilitation of stroke

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted gait training
Description: Investigators will use robot-assisted gait training for rehabilitation of stroke

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Investigators will use only conventional treatment without robot-assisted gait training
Study: NCT00762489

Intervention type: OTHER
Group type: OTHER
Intervention: Temporal artery thermometer temperature
Description: Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.

Intervention type: OTHER
Group type: OTHER
Intervention: Temporal artery thermometer temperature
Description: Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
Study: NCT01110915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Advisa MRI Implantable Pulse Generator (IPG)
Description: Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Advisa MRI Implantable Pulse Generator (IPG)
Description: Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic CapSureFix MRI™ active fixation MRI lead
Description: The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CapSureFix MRI™ active fixation MRI lead
Description: The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
Study: NCT02432365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 7-day cycle schedule of paclitaxel (60 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 7-day cycle schedule of cisplatin (40 mg/m2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy and bilateral pelvic lymphadenectomy
Description: 2 weeks after last course of neoadjuvant chemotherapy
Study: NCT03329352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Full-Face Mask
Description: The F\&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
Study: NCT04219163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL-1.CAR T cells
Description: Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2
Study: NCT04216732

Intervention type: OTHER
Intervention: Blood Pressure Measurement
Description: Undergo blood pressure measurement

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT02948842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Histolyticum Collagenase
Description: 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.08ml of injectable normal saline
Study: NCT00626262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral and Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral and Intravenous
Study: NCT00578565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
Study: NCT02360618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: See Group Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: See Group Description
Study: NCT04190186

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertable Cardiac Monitor
Description: Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
Study: NCT01665365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning
Description: Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
Study: NCT02709395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navina Smart
Description: Transanal irrigation at the same frequency as subject used before enrollment.
Study: NCT02459314

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant sterol and soluble fiber-enriched soymilk
Description: Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soymilk
Description: Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
Study: NCT04085523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TransCon CNP
Description: Weekly subcutaneously injection of placebo.
Study: NCT01108575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMST
Description: inspiratory muscle strength training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IMST
Description: sham inspiratory muscle strength training
Study: NCT01649856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab [MabThera/Rituxan]
Description: 375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
Study: NCT00179647

Intervention type: DRUG
Group type: OTHER
Intervention: lenalidomide
Description: Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens